Neoadjuvant immune checkpoint blockade in resectable hepatocellular carcinoma: A systematic review and meta-analyisis. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

Trends and disparities in palliative care utilization among patients with anal cancer: A ten-year retrospective study. Preliminary phase 1/1b dose expansion results of the bifunctional EGFR/TGFβ ...

Pan-cancer microsatellite instability testing using a multiplex assay including long mononucleotide repeats. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium.

Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...

This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.

Impact of inpatient palliative care consultation on end-of-life care among patients with esophageal cancer. Preliminary results from the multicenter, randomized phase III trial (SCIENCE): Comparing ...

Disparities in organ preservation rate for high-risk stage I rectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a ...

Niraparib in patients with BRCA-mutated unresectable or recurrent biliary tract, pancreatic and other gastrointestinal cancers: An investigator-initiated phase 2 trial (NIR-B trial). This is an ASCO ...

Efficacy and safety of intraperitoneal paclitaxel based regimens in patients with gastric cancer and peritoneal metastasis: A systematic review and meta-analysis. Envafolimab in combination with ...

Real-world treatment patterns, healthcare resource utilization (HCRU), and costs in newly diagnosed patients with rectal cancer (RC) in the United States (US). This is an ASCO Meeting Abstract from ...

dMMR/MSI tumour occurrence during follow-up of patients with Lynch syndrome treated with immune checkpoint inhibitors for a metastatic digestive cancer between 2015 and 2024: A retrospective ...

Clinicopathological factors related to survival in gastroenteropancreatic neuroendocrine tumors (GEP-NET): 20 years experience in the American British Cowdray Medical Center. This is an ASCO Meeting ...